IRulya Therapeutics Inc. (IRLA)
IRLA trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | IRLA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2019 |
| SEC CIK | 0001662774 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-13 |
| Cash and burn | $116.0M cash; operating cash flow -$11.7M a quarter. | Report 2026-06-30 |
| Shares outstanding | 10,841,470 (2026-11-05); 55,681,490 a year earlier; 42,868,947 three years earlier. 1y figure adjusted for splits (1-for-200 overall); 3y figure adjusted for splits (1-for-200 overall). | Cover page 2026-11-05 |
| Reverse splits, 3 years | 2; latest 1-for-20 on 2026-06-30 | Source 2026-06-30 |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-07-31 |
| Exchange deficiency notices, 12 months | 2 (8-K item 3.01) | 8-K 2026-09-04 |
| Auditor | BDO USA, P.C., San Jose, California, United States | PCAOB Form AP 2026-04-16 |
| Late filings, 12 months | 1 NT notice | NT 10-K 2026-04-01 |
| Insider trades, 12 months | Bought $0, sold $174K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | Not filed | -$75.5M | -$18.9M | $116.0M | $0 | Needs four quarters | 10-Q 2026-08-14 |
| Q1 2026 2026-03-31 | Not filed | $35.9M | -$7.6M | $18.2M | $0 | Needs four quarters | 10-Q 2026-05-11 |
| Q4 2025 2025-12-31 | Not filed | -$39.5M | -$10.5M | $5.8M | $0 | Needs four quarters | 10-K 2026-04-10 |
| Q3 2025 2025-09-30 | Not filed | -$13.4M | -$9.9M | $6.5M | $0 | Needs four quarters | 10-Q 2025-11-12 |
| Q2 2025 2025-06-30 | Not filed | -$16.0M | -$11.4M | $16.8M | $17.0M | Needs four quarters | 10-Q 2026-08-14 |
| Q1 2025 2025-03-31 | Not filed | -$15.0M | -$9.6M | $7.8M | $15.3M | Needs four quarters | 10-Q 2026-05-11 |
| Q4 2024 2024-12-31 | Not filed | -$12.5M | -$7.6M | $6.2M | $14.3M | Needs four quarters | 10-K 2026-04-10 |
| Q3 2024 2024-09-30 | Not filed | -$5.5M | -$7.3M | $2.7M | $14.9M | Needs four quarters | 10-Q 2025-11-12 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2026-07-31 |
| Latest annual report | 10-K | 2026-04-10 |
| Latest quarterly / interim | 10-Q | 2026-11-13 |
| Latest current report | 8-K | 2026-11-13 |
| Latest proxy | DEFA14A | 2026-10-02 |
Source: SEC EDGAR submissions feed, 473 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +28.4% |
| 1 month | +42.8% |
| 3 months | +22.8% |
| Year to date | -94.1% |
| 1 year | -88.2% |
| From 52-week high | -95.5% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| SLBT | SL Science Holding Limited | $0.7195 | -3.42% | $403.5M |
| TECX | Tectonic Therapeutic Inc. | $20.98 | -0.76% | $418.5M |
| TVGN | Tevogen Inc. | $6.22 | +3.67% | $422.2M |
| ALEC | Alector Inc. | $2.57 | +1.18% | $382.6M |
| FENC | Fennec Pharmaceuticals Inc. | $12.76 | +9.81% | $450.5M |
| CADL | Candel Therapeutics Inc. | $5.81 | -6.29% | $455.8M |
| CCCC | C4 Therapeutics Inc. | $2.65 | -3.99% | $348.0M |
| RGNX | REGENXBIO Inc. | $7.32 | -4.19% | $484.0M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier